Carmot Therapeutics, Inc., a clinical-stage biotechnology company, is thrilled to be participating in the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA! At the event, the firm will be sharing multiple research findings from their groundbreaking efforts in the discovery of disease-modifying therapies for metabolic diseases. Be sure to check out the amazing poster presentations at the event to find out more about Carmot’s innovative work!
Explore how CT-388 and CT-868, pioneering dual GLP-1 and GIP receptor modulators, could pave the way for safe, effective weight loss in overweight and obese people with type 2 diabetes! In a live session on June 24 & 25, authors M. Chakravarthy and team will present two studies: ‘CT-388 is Safe and Produces > 8% Weight Loss in 4 Weeks’ and ‘Weight-Independent Effects of CT-868 on Glucose Homeostasis’.
Learn more about how CT-388 and CT-868 show promise to improve weight loss via biased GIP in diabetic rodent models. Don’t miss the live Clinical Therapeutics and Integrated Physiology presentations!
Carmot’s pipeline includes
CT-388, a revolutionary once-weekly, dual GLP-1/GIP receptor modulator is currently making waves in the medical world, as it embarks on its quest to help individuals struggling with managing their weight and their diabetes. A Phase 1/2a clinical trial is already underway for overweight and obese participants with and without type 2 diabetes , with additional Phase 2 trials in overweight and obese adults projected to begin in 2023 – a major breakthrough in continuing to address the challenges that come with obesity and T2D.
Carmot’s groundbreaking dual-action GLP-1/GIP receptor modulator CT-868 is on its way to revolutionizing how we treat type 1 and type 2 diabetes. After completing a Phase 1 clinical trial in healthy overweight and obese adults, a Phase 2 trial in obese adults with T2D, and a MOA study, the team is now ready to explore CT-868’s potential with type 1 diabetes. Set to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2023, CT-868 could help make life easier for those living with diabetes.
CT-996, a small molecule GLP-1 receptor agonist that is administered orally, has recently advanced to Phase 1 clinical trials in overweight and obese individuals who are otherwise healthy. This promising molecule has the potential to revolutionize treatments for these conditions.
The development of a long-acting peptide tyrosine-tyrosine (PYY) analogue is underway, and it promises to revolutionize the medical industry. With the potential to have an extended duration of physical and psychological effects, this peptide analogue has the potential to impact many diseases and treatments. With further clinical studies and research, this novel peptide could revolutionize the landscape of medicine as we know it.
About Carmot Therapeutics
Carmot Therapeutics is pioneering a new era of disease-modifying treatments for metabolic diseases like obesity and diabetes. Leveraging the revolutionary drug discovery platform Chemotype Evolution, we are on the cutting edge of finding novel incretin receptor targets and developing a comprehensive pipeline of potentially transformative therapeutics. We have three clinical candidates in the pipeline: CT-388, CT-868, and CT-996 – a once-weekly dual GLP-1/GIP receptor modulator, a once-daily dual GLP-1/GIP receptor modulator and an oral small molecule GLP-1 receptor agonist, respectively. Through our research, we are hoping to make an impact by providing significant weight loss and improved glycemic control for people living with metabolic diseases.